GLP-1s and asthma: promising signals, different kinds of evidence

The question is fewer attacks, not simply easier breathing

It is easy to put several different experiences under the heading of better breathing: feeling less winded, sleeping better, using a reliever less often, or having fewer asthma attacks. They are not interchangeable outcomes. When reading a GLP-1 asthma headline, I first look for the event that researchers actually counted. An asthma diagnosis, an adverse-event report and a clinician-confirmed exacerbation can produce different datasets. This matters especially when a weight-management result is discussed alongside a respiratory finding. Ask whether the study measured the symptom you want to understand, and whether its participants resemble you.

The earlier diabetes cohort was observational

Foer and colleagues compared new users of several diabetes medicines who also had asthma. The GLP-1 group included 448 people, and follow-up for the main comparison was six months. Exacerbation counts were lower among GLP-1 users than among the active comparator groups. This was a retrospective electronic-records study, however, rather than treatment assigned at random. Prescribing decisions and differences in patients or care could influence the association despite adjustment. Its population had type 2 diabetes, so the finding should not be casually extended to everyone with asthma or to any particular modern weight-loss program.^[1]

What the 2026 SELECT subgroup adds

A 2026 American Diabetes Association conference abstract examined asthma-related adverse or serious adverse events among 1,190 SELECT participants reporting asthma at baseline. SELECT assigned semaglutide or placebo randomly, but this respiratory question was examined after the fact. The parent trial involved adults aged at least 45 with overweight or obesity and established cardiovascular disease. Those selection criteria matter. A post hoc subgroup within a cardiovascular trial is useful evidence for further investigation, but is different from a trial designed around asthma control, inhaler use or a standardized exacerbation outcome in a general asthma population.^[2] The parent population is explained in our SELECT cardiovascular trial guide; its heart outcome should not be relabeled as an asthma result.

Do not combine the studies into a personal forecast

The cohort and SELECT subgroup have different treatment comparisons, populations and event definitions. Adding their numbers together or presenting one as confirmation of the other would hide those differences. I would also resist turning a relative effect from a conference poster into a promised number of attacks avoided. A useful personal discussion starts with your own history: what counts as an attack, how often it happens and how your clinician currently measures control. Keep the original study label beside any reported result. Promising is an appropriate description of a research direction; proven asthma prevention is a much stronger claim.

Your action plan still governs asthma care

NHLBI describes asthma care as an individualized combination of medicines, monitoring and a written action plan. That plan identifies daily treatment, how to respond to worsening symptoms and when to seek urgent help. A weight-management prescription does not replace those instructions. If you are having a breathing emergency, follow your action plan and obtain emergency care rather than waiting to see whether a metabolic medicine helps. At a routine review, ask your asthma clinician whether any change in symptoms warrants reassessment. Do not reduce a controller or reliever because a news story or an online weight-loss intake suggests a respiratory benefit.^[3]

Bring two separate timelines to the appointment

CDC emphasizes knowing your asthma triggers and using a personal action plan. For a useful conversation, bring the timing of respiratory symptoms and the timing of medication or major health changes as separate records. Include recent urgent visits, steroid courses and any change in reliever use if those are already tracked in your care. This helps you describe what happened without deciding the cause yourself. The question is not whether a smaller weight number proves improved asthma. It is whether your treating clinician sees a meaningful change in control and needs additional assessment or a revised plan.^[4]

Choose coordination before an online program

If a clinician is considering treatment for obesity or diabetes, ask how the prescribing service communicates with the team managing your asthma. A platform may be convenient without providing respiratory specialty care. I would want to know where the medication list goes, how new symptoms are assessed and which team handles urgent breathing concerns. Check the scope of the actual appointment rather than inferring it from a broad wellness label. Our commercial reviews compare service information, not asthma outcomes, and cannot establish that a provider or medication is suitable for your circumstances. Start with the service questions in our telehealth appointment checklist. For an appointment-marketplace model, see our Sesame Care review and confirm the individual clinician’s scope before booking.

What would make the next result more persuasive

I would look for a prespecified respiratory endpoint, an appropriate comparison group, enough follow-up to capture seasonal variation, and clearly reported safety and treatment discontinuation. A dedicated trial could also distinguish asthma symptoms from other reasons for breathlessness. Until then, keep three questions together: what is the established reason for prescribing, what does your asthma clinician recommend, and what remains experimental? That approach allows genuine interest in emerging evidence without making an expensive service decision on a claim the study did not test. Better study design matters more than a more enthusiastic headline.

Continue your research

• GLP-1s for binge-eating disorder: what the trials actually measured
• Liraglutide and migraine: why the small pilot is not a treatment promise
• GLP-1s after bariatric surgery: recurrence and a suboptimal response are different